The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Chromadex Corp (NASDAQ: CDXC) was $7.94 for the day, up 1.28% from the previous closing price of $7.84. In other words, the price has increased by $1.28 from its previous closing price. On the day, 0.68 million shares were traded. CDXC stock price reached its highest trading level at $8.0 during the session, while it also had its lowest trading level at $7.68.
Ratios:
Our analysis of CDXC’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.82 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 51.92. For the most recent quarter (mrq), Quick Ratio is recorded 3.06 and its Current Ratio is at 3.57. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
On August 11, 2022, B. Riley Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $2.40.
On March 08, 2022, ROTH Capital started tracking the stock assigning a Buy rating and target price of $7.ROTH Capital initiated its Buy rating on March 08, 2022, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 07 ’25 when Lopez Carlos Luis bought 273 shares for $7.86 per share. The transaction valued at 2,146 led to the insider holds 2,251 shares of the business.
Jaksch Frank L Jr sold 37,161 shares of CDXC for $229,956 on Dec 13 ’24. The Director now owns 244,179 shares after completing the transaction at $6.19 per share. On Dec 13 ’24, another insider, Frank Jaksch Jr., who serves as the affiliate of the company, bought 37,161 shares for $6.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDXC now has a Market Capitalization of 617338176 and an Enterprise Value of 576807552. As of this moment, Chromadex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 75.40, and their Forward P/E ratio for the next fiscal year is 38.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.20 while its Price-to-Book (P/B) ratio in mrq is 13.32. Its current Enterprise Value per Revenue stands at 5.791 whereas that against EBITDA is 67.542.
Stock Price History:
The Beta on a monthly basis for CDXC is 2.12, which has changed by 1.9298892 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, CDXC has reached a high of $9.18, while it has fallen to a 52-week low of $2.02. The 50-Day Moving Average of the stock is 31.38%, while the 200-Day Moving Average is calculated to be 73.24%.
Shares Statistics:
CDXC traded an average of 817.51K shares per day over the past three months and 2875090 shares per day over the past ten days. A total of 77.33M shares are outstanding, with a floating share count of 49.23M. Insiders hold about 36.68% of the company’s shares, while institutions hold 29.21% stake in the company. Shares short for CDXC as of 1740700800 were 2105794 with a Short Ratio of 2.58, compared to 1738281600 on 2112969. Therefore, it implies a Short% of Shares Outstanding of 2105794 and a Short% of Float of 4.18.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
